01. Doctor Overview
Dr. Chi-Fu Jeffrey Yang is a thoracic surgeon with experience treating various conditions, such as mesothelioma. He practices minimally invasive surgery techniques at Massachusetts General Hospital Cancer Center. He is also an Assistant Professor of Surgery at Harvard Medical School.
Dr. Yang is passionate about providing high-quality care for patients. He helped care for his grandfather during college, who passed away from lung cancer. As a doctor, he carries the experience with him and treats all of his patients like family.
Dr. Yang excels at minimally invasive treatment methods, such as robotic surgeries. These methods may offer many benefits for eligible patients, including quicker recovery times compared to open surgery.
Dr. Yang’s work also emphasizes lung disease awareness, education and research. Massachusetts General Hospital Cancer Center is the top research hospital in America. Here, Dr. Yang’s clinical research focuses on thoracic oncology. He has written or contributed to more than 100 publications, largely related to lung disease. Dr. Yang is also an editorial board member for three prominent academic resources:
- The Journal of Thoracic and Cardiovascular Surgery
- The Journal of Thoracic Diseases
- The Society of Thoracic Surgeons Online Curriculum
In 2018, Dr. Yang founded the American Lung Cancer Screening Initiative. This non-profit focuses on raising awareness on the importance of lung cancer screenings. In 2020, Dr. Yang worked with Congress to introduce two pieces of legislation. These resolutions, H.R. 1192 and S.R. 780, promoted practices for early detection of lung cancer. The Senate resolution was reintroduced in 2021 as S.R. 462.
Dr. Yang has received many accolades and awards for his work thus far. As a doctor, he intends to continue advancing lung disease research and treatment. As an assistant professor, he hopes to provide future doctors with tools and knowledge to do the same.
02. Doctor Fast Facts
Doctor Fast Facts
Main Specialty: Thoracic Surgery
Other Interests & Specialties: Biochemistry, chest wall tumors and reconstruction, clinical research, esophageal cancer, lung cancer, lung nodules and ground-glass opacities, mesothelioma, minimally invasive surgery, robotic surgery, sarcomas, thymoma and video-assisted thoracic surgery (VATS).
Certifications, Awards & Accolades: American Board of Surgery Certification in General Surgery, American Board of Thoracic Surgery in Thoracic Surgery, editorial board member of the Journal of Thoracic and Cardiovascular Surgery, the Journal of Thoracic Diseases and the Society of Thoracic Surgeons Online Curriculum, founder of the American Lung Cancer Screening Initiative, recipient of the 2021 AATS Foundation Surgical Investigator Award, recipient of the 2021 Harvard Medical School Charles McCabe Faculty Prize for Excellence in Teaching, recipient of the 2021 Harvard Medical School Dean’s Community Service Faculty Award
Education & Experience:
- Medical Degree from Harvard Medical School
- Internship in General Surgery at Duke University Medical Center
- Fellowship in Cardiothoracic Surgery at Stanford University Medical Center
- Residency in General Surgery at Duke University Medical Center
The Impact of Adjuvant Hemithoracic Radiation on Outcomes in Patients with Stage I-III Malignant Pleural Mesothelioma: A Dual Registry Analysis. Annals of Surgery. June 2021. doi: 10.1097/SLA.0000000000004976
The Role of Neoadjuvant Chemotherapy in Patients With Resectable Malignant Pleural Mesothelioma-An Institutional and National Analysis. Journal of the National Cancer Institute. November 2020;112(11):1118-1127. doi: 10.1093/jnci/djaa002
Impact of Age on Long-Term Outcomes of Surgery for Malignant Pleural Mesothelioma. Clinical Lung Cancer. September 2016;17(5):419-426. doi: 10.1016/j.cllc.2016.03.002
Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database. Journal of Surgical Research. June 2015;196(1):23-32. doi: 10.1016/j.jss.2015.01.043
Estimating the Impact of Extended Delay to Surgery for Stage I Non-Small-Cell Lung Cancer on Survival. Annals of Surgery. May 2021;273(5):850-857. doi: 10.1097/SLA.0000000000004811
Stereotactic Body Radiotherapy versus Delayed Surgery for Early-Stage Non-small-cell Lung Cancer. Annals of Surgery. December 2020;272(6):925-929. doi: 10.1097/SLA.0000000000004363
A National Analysis of Short-term Outcomes and Long-term Survival Following Thoracoscopic vs Open Lobectomy for Clinical Stage II Non-small-cell Lung Cancer. Annals of Surgery. March 2019;273(3):595-605. doi: 10.1097/SLA.0000000000003231
A National Analysis of Long-term Survival Following Thoracoscopic versus Open Lobectomy for Stage I Non-small-cell Lung Cancer. Annals of Surgery. January 2019;269(1):163-171. doi: 10.1097/SLA.0000000000002342
Long-term Survival After Surgery Compared with Concurrent Chemoradiation for Node-negative Small Cell Lung Cancer. Annals of Surgery. December 2018;268(6):1105-1112. doi: 10.1097/SLA.0000000000002287